BiotechTV

BT Slingsby describes his education and career abroad, which ultimately led him to found and manage the largest life sciences VC firm in Japan, Catalys Pacific. He describes the dual role of taking assets from Japan and building companies around them inte

The phase 3 success of Merck and Moderna's personalized cancer vaccine brought biotech to the forefront and lifted the entire sector.

Interviewed by the Sisterhood Editorial Board Chair Abbey Jenkins, Katherine Stueland describes how the mission of getting the company on stable ground through financial discipline and a sharper focus on strategy has enabled it to thrive and deliver on it

While the overall sector was flat this week, there were big movers on regulatory updates, including Inovio and Capricor. Meanwhile, AbCellera scored a big trial win while Sionna crashed after its cystic fibrosis therapy did not show additional benefit on

CEO Amber Salzman discusses the benefit of the raise, and contrasts the funding environment in biotech today versus previous years. Plus, she describes the unmet need in FSHD and how AI has already been helping the company understand the patient experienc

She believes we are in the early days of this type of work and that it will empower scientists, physicians and caregivers to focus on more important work that really matters.

Founder and CEO Kazu Okuda describes the effort to make this technology a reality. He says they have already published evidence that the device can measure the onset of and predict the remission of depression, and the ultimate goal is to get it to a place

George Petrocheilos describes going to school at Hopkins and the relationships formed there that would ultimately lead down the road to specializing in healthcare investing. He discusses starting in life sciences investing at Camden Partners, and then co-

Biotech markets rallied on the FDA approvals of Moderna's mRNA flu vaccine and Replimune's viral immunotherapy for melanoma in hopes that it confirms a constructive direction by new leadership there.

Co-Founder, President & CEO Greg Verdine describes the toxicity issues associated with the immuosupressive drugs that transplant recipients currently receive, and explains how LIFE-001 is different. Plus, given how the therapy is designed to safely preven